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Background: Two new immunoassaymethods for aldosterone assay using automated platforms recently became
available into market. The main aim of the present study is to evaluate the analytical performance of these auto-
mated direct immunoassay methods, and also to compare their analytical characteristics to those of the most
popular RIA and EIA methods used in an Italian External Quality Assessment (EQA) study.
Methods: In this study analytical performances of two aldosterone immunoassays using the IDS iSYS andDiaSorin
LIAISON fully automated platforms, were evaluated. Results obtained with the two platforms in EDTA plasma
samples of healthy subjects and patients were compared with those obtained by RIA and EIA methods used in
the Italian EQA scheme, named Immunocheck study.
Results: The two automated methods showed similar analytical performances: LoD 83.9 vs 92.2 pmol/L, LoQ
104.4 vs 111.1 pmol/L, respectively; moreover, the within-run and total imprecision values showed CV%
between 8.1 and 14.1 for samples with 180.8 and 387.2 pmol/L concentration for both methods. There was a
close linear regression between methods, however we found a signiﬁcant proportional bias between LIAISON
and iSYSmethods. The EQA samples results obtainedwith these twomethodswere highly correlated to the con-
sensus mean values.
Conclusions:Our data indicate that aldosterone valuesmeasuredwith the two automatedmethods actually show
better reproducibility, shorter laboratory Turn Around Time (TAT) and require less “hands on labor” compared to
RIA and EIA immunoassays. However, in our study signiﬁcant biaswas observed in result comparison, thismeans
that translating aldosterone concentration in clinical information an appropriate deﬁnition of reference ranges
for each method is mandatory.© 2015 Elsevier B.V. All rights reserved.1. Introduction
Aldosterone is a corticosteroid hormone produced by the outer sec-
tion (zona glomerulosa) of the adrenal cortex. Recent studies reported
that also other tissues than adrenal gland (such as vasculature and
heart) may produce aldosterone [1]. The limited studies that have
been performed suggest that aldosterone's regulation in these tissues,ca ed Ematologia, Ospedale San
+39 0 444 753230.
. Fortunato), tina@ftgm.it
ia@gmail.com (M. Franzini),
ifc.cnr.it (S. Giovannini),
din), passino@ftgm.itmay be under the same control as aldosterone production by the adre-
nal cortex [1].
From a clinical point of view, the aldosterone assay is recommended
by international guidelinesmainly for screening and diagnosis of primary
aldosteronism [2–4]. Recent data suggest that primary aldosteronism is
present in about 10% of patients with primary arterial hypertension, in
particular those with the so-called low-renin hypertension syndrome,
characterized by arterial hypertension, hypokalemia and circulating low
renin levels.
From an analytical point of view, aldosteronemeasurement in blood
or urine samples actually has some analytical critical points due to
the low amount of the steroid and the presence of a lot of possible inter-
fering substances in body ﬂuids. Competitive immunoassays are
the methods usually used for the measurement of aldosterone. About
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were RIA methods [5], which usually included a preliminary extraction
and/or chromatographic puriﬁcation step in order to improve the
analytical sensitivity and accuracy [6]. More recently, direct (without
extraction or puriﬁcation step) immunoassay competitive methods,
using antisera andmonoclonal antibodies with higher afﬁnity and spec-
iﬁcity for the steroid molecule and non-isotopic labels, were set up for
the measurement of aldosterone in all body ﬂuids, including also saliva
[6–10].
Accuracy of aldosteronemeasurement in biological ﬂuids can be im-
proved using several gas-chromatographic (GS) or high-performance
liquid chromatographic (HPLC) mass spectrometry (MS) techniques
[11–13]. Although these techniques are considered a reference method
that provides both accurate results and excellent speciﬁcity, these
methods are more expensive and time consuming, and less practicable
than immunoassay methods. Furthermore, these methods usually
require sample preparation, such as chemical derivatization, and dedi-
cated laboratory staff. Therefore, due to the lack of automation and com-
plexity, GS-MS and HPLC-MS methods are not actually used by the
majority of the routine clinical services [12]. In fact, the data from
inter-laboratory quality control surveys (External Quality Control:
EQA) show that only very few laboratories use MS: e.g. in the survey
set RAP (speciﬁc control for Aldosterone and Renin) of the College of
American Pathologists (CAP) program only a RIA method is used for at
least 20 laboratories (theminimumnumber of results for a statistical sig-
niﬁcance) and, among 86 laboratories participating to an Italian national
program [i.e., Immunocheck program by QualiMedLab (http://www.
qualimedlab.it)], none reports Aldosterone measurement performed
by MS.
Very recently, some immunoassay methods for aldosterone assay,
using fully automated platforms, became available into market; these
newmethods should share analytical performances better than the pre-
vious competitive RIA and EIA methods. The main aim of the present
study is to evaluate the analytical performances of two automateddirect
immunoassay systems, which recently became commercially available
(i.e., LIAISON platform by DiaSorin, Saluggia, Italy, and iSYS platform
by IDS Ltd., Boldon, UK) in terms of reproducibility of measurements
and correlation of results obtained with both the automated analyzers
with RIA and EIAmethods. The second aim is to evaluate the differences
of results obtained in the two referral laboratories, using these automat-
ed immunoassay systems in the same clinical samples, collected from
healthy subjects and patients with cardiovascular disease and/or
hyperaldosteronism. Furthermore, to assess the accuracy (true value)
of measurements, the data produced with the most used immunoassay
methods by all participant laboratories to an Italian EQA scheme were
compared with those measured with the two automated systems in
some control samples.
1.1. Materials and methods
1.1.1. Assay methods
The reproducibility of measurements, within and between assays,
and feasibility of two direct immunoassays using automated platforms
were independently evaluated in two referral Italian laboratories
(i.e., the Department of Laboratory Medicine, Fondazione CNR–Regione
Toscana G. Monasterio, Pisa, and Clinical Chemistry Laboratory, San
Bortolo Hospital, Vicenza).
One of the automated immunoassay system evaluated for aldoste-
rone assay was the competitive chemiluminescence assay using
LIAISON platform (code 310450, DiaSorin, Saluggia, Italy). The principle
components of this immunoassay consist of magnetic particles coated
with anti-sheep antibody that bind the sheep anti-aldosterone mono-
clonal antibody. An aldosterone labeled conjugate containing an
isoluminol derivative competes with steroid hormone from the calibra-
tors, control and patient samples. The light signal ismeasured as relative
light unit (RLU), which is inversely proportional to the concentration ofaldosterone present in calibrators, control or patient samples. The labo-
ratory Turn Around Time (TAT), understood as the time to complete the
analytical procedure, is less than 60 min. According to the
manufacturer's instructions the measurable range is 83.1–2770 pmol/L
and any value that reads below 83.1 pmol/L [14].
The analytical performance of the IDS-iSYS aldosterone method
(code IS-3300) using the iSYS platform (IDS Ltd., Boldon, UK) was also
evaluated in the two study referral laboratories. This immunoassay sys-
tem is based on chemiluminescent technology. A biotinylatedmonoclo-
nal anti-aldosterone antibody is incubated with the sample, after an
incubation step and aldosterone acridinium conjugate is added and,
after a further incubation step, streptavidin coated magnetic particles
are added. Following a third incubation step, the antibody–aldosterone
complex was separated by the unbound aldosterone using a magnet.
After a washing step and addition of trigger reagents, the light emitted
by the acridinium label is inversely proportional to the concentration
of aldosterone in the original sample. The TAT is less than 60 min.
According to the manufacturer's instructions for bulletin use (REF
IS-3300) the reportable range of the IDS-iSYS aldosterone method is
102.5–3656 pmol/l [15].
The performances of these two automated immunoassay systems
were compared to those of some RIA methods for aldosterone in the
two referral laboratories. The ﬁrst RIA method evaluated was the kit
RIA ALDOCTK-2 (code P2714/100 tubes, DiaSorin, Saluggia, Italy). The
second RIA method used was Aldosterone Coat-A-Count (Siemens,
Los Angeles USA). The principle of both RIA methods is based on the
competition between 125I-labeled aldosterone and steroid molecules
contained in calibrators or samples to be assayed. These competitive
immunoassays are based on the use of antibody-coated tubes for B/F
separation. The TAT is about 22–24 h (i.e., using overnight incubation)
for both RIA assays.
1.1.2. Analytical performance of automated immunoassay methods
The analytical performances of the two automated immunoassays
were determined in accordance with the CLSI EP17-A protocol [15] for
evaluating the limits of blank (LoB) and detection (LoD), the CLSI EP5-
A2 protocol [16] for the assay reproducibility by repeatedly measuring
2 different EDTA plasma samples throughout 20 consecutive working
days. These evaluations were carried out separately in the two referral
laboratories using different sets of samples. The LoB value was assessed
by measuring the saline solution (considered as the blank of the meth-
od) in 5 different runs for 65 times using two different lots of calibrators.
The RLU value corresponding to LoB was calculated according to the
formula RLULoB =mean value− 1.645 SD [15]. The LoD was calculated
according to the formula: LoD = LoB + 1.645 SD [16], where SD is the
standard deviation of measured values of a sample pool with very low
aldosterone concentration. The between-runs imprecision proﬁle was
performed by repeatedly measuring several EDTA blood samples
collected from healthy subjects and patients in 20 different runs. In par-
ticular, in the Laboratory of Fondazione G. Monasterio, the aldosterone
assay analytical performances using LIAISON platform were evaluated
and those of automated iSYS platform (IDS— Boldon, UK)were evaluat-
ed at “San Bortolo” hospital laboratory in Vicenza.
1.1.3. Clinical samples
The referral laboratories collected samples from healthy subjects or
patients for the evaluation of analytical performances and the compari-
son of clinical results obtained with the two automated immunoassay
systems. All subjects enrolled have released an informed consent.
In the clinical ward of the FondazioneG.Monasterio, 367 blood sam-
ples (8–10 mL) of 168 apparently healthy subjects and 199 patients
with cardiovascular disease were collected in EDTA polypropylene
tubes between 08:00 and 09:00 a.m. after overnight fast in supine
position at rest for at least 15 min. After centrifugation at 3000 ×g for
10 min, the plasma was collected in various aliquots of 0.5 mL, put in
polypropylene, and ﬁnally stored at −20 °C until the assay. Healthy
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tion, laboratory tests, ECG and cardiac imaging analysis (echocardiogra-
phy). We excluded all subjects presenting cardiac or systemic acute or
chronic diseases, such as previous myocardial infarction, heart failure,
coronary heart disease, hypertension, diabetes, kidney disease, obesity,
tumor, hepatitis, and pulmonary diseases. Subjects using drugs up to
two weeks before aldosterone assay, except for substitutive hormonal
therapy, were also excluded.
At San Bortolo Hospital plasma EDTA samples were collected, from
20 apparently healthy male and female volunteers, aged 21–65 years,
with normal blood pressure and fasting glucose levels. The exclusion
criteria were a need for prescription medications or a physician-
prescribed restricted diet, pregnancy, breastfeeding, and the use of
oral contraceptives. The blood samples were drawn between 7.00 a.m.
and 12.00 a.m. from subjects in a standing or supine position: the stand-
ing sampleswere drawn after the subjects had beenwalking for 2 h, and
the supine sampleswere drawn after the subjects had been lying supine
for at least 1 h. The samples were handled in the same way previously
described. Moreover, the Aldosterone Coat-A-Count and ALDOCTK-2
RIA methods were used to compare results obtained with iSYS system
in 220 remnant plasma EDTA samples from routine activity; the sam-
ples were stored at−80 °C and then reassayed in the same day with
all the methods in evaluation. Urinary aldosterone measurements, per-
formed with iSYS system and ALDOCTK-2 RIA, were evaluated in 88
remnant samples of 24 h urine collections. Before analysis urine sam-
ples were hydrolysed using a 3 fold dilution with 0.2 N HCl, overnight
incubation at room temperature and a further 10 fold dilutingwith a so-
lution containing 6.5 g/dL of bovine albumin in a phosphate buffer at
pH 7.4.Table 1
Comparison of analytical sensitivity parameters of the immunoassay methods for plasma
aldosterone using the LIAISON and iSYS platforms.
Methods LoB, pmol/L LoD, pmol/L LoQ at 20% CV, pmol/L
LIAISON platform 50.0 83.9 111.1
iSYS platform 53.1 92.2 104.41.1.4. External Quality Assessment (EQA) scheme
The “Immunocheck” External Quality Assessment (EQA) scheme,
conducted by QualiMedLab-CNR (Pisa, Italy) in co-operation with
ProBioQual (Lyon, France), was established since the beginning of the
80s. QualiMedLab is a spin-off of the Italian Research Council (CNR)
and operate together with the Institute of Clinical Physiology of the
CNR and the Fondazione G. Monasterio in Pisa, Italy. Details of how
QualiMedLab operates can be found on its website (http://www.
qualimedlab.it). In particular, the 90 European participant laboratories
to 2013 EQA cycle produced 726 aldosterone measurements (including
55 Italian laboratories), while the 111 participant laboratories to 2014
EQA cycle produced 980 aldosterone measurements (including 67 Ital-
ian laboratories).
For the preparation of study samples, several EDTA plasma samples
were pooled together to obtain a sample poolwithﬁnal volumeof about
100 mL, which was immediately stored at −20 °C. All samples were
tested for the absence of HBsAg, antiHCV, and antiHIV. Plasma pools
were prepared using residuals from samples collected from apparently
healthy subjects and patients with cardiovascular diseases, collected in
the Laboratory of the Fondazione G. Monasterio. Blood samples collect-
ed from approximately 30–50 subjects/patients were included in every
study sample. A different poolwas created for each control sample using
plasma with similar aldosterone concentration. Subjects and patients
gave the informed consensus for the use of their residual blood samples
in the study.
Study samples were sent by mail as lyophilized materials. Lyophili-
zation procedure was performed by Polymed (Sambuca, Firenze, Italy)
within two weeks after preparation of sample pools. Stored sample
pools, were defrozen, then distributed in approximately 200 vials
(each containing a plasma/serum volume of 3.0 mL), and ﬁnally lyoph-
ilized. Plasma aldosterone concentrations of all the study samples were
measured before and after the lyophilization by the reference laboratory
in order to evaluate the recovery of lyophilization procedure and the
stability of aldosterone in the matrix samples. Samples with unreliable
results, exceeding 3 standard deviations, were discarded.1.2. Statistical analysis
Standard statistical analyses were performed using the Stat-View
5.0.1 program (1992–98, SAS Institute Inc., SSA Campus Drive, Cary, NC,
USA). Both parametric and not parametric analyses were performed,
the Tukey test was used for mean comparison.
The statistical analysis for EQA study was performed by
QualiMedLab (http://www.ifc.cnr.it/eqas/). Total variability of the
results obtained in the EQA study was estimated by averaging the CVs
computed from the results of each study sample. This variability in-
cludes both systematic between-methods differences and differences
introduced by the laboratories. The imprecision of the methods was es-
timated by averaging the CVs of the results produced by participants
(using the same method) for the same study sample. Therefore, the
reported average CVs, used for the calculation of imprecision proﬁles,
were an estimate of the within-method, between-laboratories impreci-
sion achieved by themethodduring themulticenter collaborative study.
The consensusmeanwas calculated as themean value of the all aldoste-
rone concentrations measured by all participant laboratories in the
same control samples. The values are reported as a mean ± SD, if not
otherwise stated.
1.3. Results
1.3.1. Analytical performance of automated immunoassay methods
In Table 1 data obtained for analytical sensitivity are showed. For the
LIAISONmethod, the LoB value was calculated by considering themean
RLU value (132523 RLU, SD = 9339 RLU) obtained by repeatedly mea-
suring (n = 65) a sample containing saline solution in 5 different runs
using two different lots of calibrators. The RLU value of the 1.645 SD
(i.e., 117161 RLU) was then interpolated on the mean standard curve
of LIAISON method (RLU = 131,791.174− 812.374 aldosterone, R =
0.947, n= 125) to obtain the respective LoB value: 50.0 pmol/L of aldo-
sterone (Table 1). The LoD was calculated according to the formula:
LoD = LoB + 1.645 SD, using a plasma sample with very low aldoste-
rone concentration (mean concentration 65.6 pmol/L, CV = 31.2%,
n = 20). As a result, the calculated LoD value was 83.9 pmol/L, respec-
tively (Table 1). For iSYS aldosterone concentrations of 53.1 pmol/L for
LoB, 92.2 pmol/L for LoD, and 104.4 pmol/L for LoQ value at 20% CV
were respectively found (Table 1) [16]. The assay reproducibility of
the aldosterone assay, evaluated in accordance with the CLSI EP5-A2
protocol [17] by repeatedly measuring 2 different EDTA plasma sam-
ples. Using LIAISON platform and samples containing on average
180.8 pmol/L (sample A) and 387.2 pmol/L (sample B) of aldosterone
respectively were 12.9 CV% and 14.1 CV% for the sample A and 8.1
CV%and10.1 CV% for sample B, forwithin-run and total imprecisions re-
spectively. Using iSYS and samples containing on average 401.7 pmol/L
(sample C) and 1293.7 pmol/L (sample D) of aldosterone respectively
were 8.4 CV% and 12.7 CV% for the sample C and 5.5 CV% and 6.2 CV%
for sample D, for within-run and total imprecisions respectively.
The between-runs imprecision proﬁles of the two aldosterone
immunoassay methods are reported in Fig. 1. The calculated limits of
quantitation (LoQ) [15] at 20% CV and 10% CV were 111 pmol/L and
264 pmol/L of aldosterone, respectively using LIAISON platform, while
the LoQ limits at 20% CV and 10% CV for the iSYS method were
104 pmol/L and 208 pmol/L.
Both automatedmethods for aldosterone showed a close linearity to
dilution test. These testswere performed in the two referral laboratories
Fig. 1. Comparison of imprecision proﬁles of the two automatedmethods for aldosterone.
The imprecision proﬁles of the two automated LIAISON and iSYS methods are shown in
the ﬁgure. The calculated equations by means of the power regression analysis were
y = 152.7×−0.571 and y = 557.4×−0.888 for the LIAISON and iSYS methods, respectively.
Fig. 2. Comparison of the aldosterone concentrations measured with LIAISON and iSYS
platforms. Part A. Linear regression between the aldosterone concentrations measured
by iSYS platform (X axis) and LIAISON platform (Y axis) in 290 plasma samples of
91 healthy subjects and 199 patients with cardiovascular diseases. Part B. Linear relation-
ship between the percent difference between the aldosterone concentrations measured
by the two automatedmethods [(LIAISON− iSYS) / mean concentration × 100], reported
in the Y-axis, and the mean aldosterone concentrations measured in the same plasma
sample using the two automated platforms, reported in the X-axis.
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rone concentrations. The linearity of the immunoassays methods was
evaluated according to the CLSI EP6-A protocol [18].
1.3.2. Comparison of results obtained with different immunoassay methods
In the referral Laboratory of Fondazione G. Monasterio, the aldoste-
rone values measured with the LIAISON platform were compared to
those found with iSYS platform in 290 plasma samples of 91 healthy
subjects and 199 patients with cardiovascular diseases. These two
immunoassay systems showed a close linear regression (LIAISON
system = 71.9 (95%CI: 52.8–91.0) + 0.873 (95%CI: 0.826–0.920) iSYS
system; R = 0.906) (Fig. 2A). A signiﬁcant bias was found between
the aldosterone valuesmeasuredwith these twomethods (mean differ-
ence LIAISON− iSYS = 37.8 ± 129.1 pmol/L; Wilcoxon Signed Rank
Test p b 0.0001). The relationship between the percent difference of
the two methods [(LIAISON− iSYS) / mean concentration × 100] and
the mean aldosterone concentration were reported in Fig. 2B. These
data indicate that there is a signiﬁcant bias (p = 0.0146) between
these two methods, which proportionally increases with the aldoste-
rone concentration, showing on average a difference of 15.0 ± 71.8%.
However, the linear regression between the difference between the
two methods and the mean aldosterone concentration measured by
the two methods is not statistically signiﬁcant (mean difference =
37.8 ± 129.1 pmol/L; R = 0.087, p N 0.10).
The correlations between the aldosterone concentrations measured
with the two automatedmethods and someRIAmethods by the referral
laboratories were also evaluated. The results obtained with the LIAISON
method in 314 plasma EDTA samples of healthy subjects and patients
with cardiovascular disease were compared to those found with the
RIA method, used for clinical routine in the laboratory. The results ob-
tained by these two methods, ranging from 181.7 to 2177.8 pmol/L,
were signiﬁcantly correlated (LIAISON method = −15.8 pmol/L
(95%CI: from −48.5 to 16.9 pmol/L) + 0.779 (95%CI: 0.724–0.834)
RIAmethod, R= 0.876); however, LIAISONmethod showed on average
lower aldosterone values compared to RIAmethod of about−11.2% (SD
118.2%, p b 0.0001 byWilcoxon Signed Rank test).Moreover, a close lin-
ear regression was found between IDS-iSYS and Siemens Coat-A-Count
RIA results in 220 EDTA plasma samples [iSYSmethod=−0.92 (95%CI:
−1.98–0.23) + 1.26 (95%CI: 1.17–1.36) RIA Siemens, R = 0.95]. In
the Bland–Altman plot the mean was −9.4 pmol/L with the range
between ±1.96 SD from−44.4 to 25.6 pmol/L. The aldosterone con-
centrations measured with iSYS platform were also found to be closelycorrelated to those obtained with the ALDOCTK-2 RIA [iSYS
method = −53.7 (95%CI: from −84.1 to −33.9) + 0.78 (95%CI:
0.71–0.84) RIA DiaSorin, R = 0.93]. In Bland–Altman plot the mean
was 40.7 pmol/L with the range between ±1.96 SD from −38.0 to
119.4 pmol/L.
Finally, in the laboratory of “San Bortolo” Hospital, aldosterone con-
centrations ranged from 50.0 to 1125 pmol/L in 88 urine samples; the
Passing–Bablok regression of iSYS against RIA DiaSorin shows a slope
of 1.20 (95%CI: 1.11–1.28) and intercept 2.1 (95%CI:1.08–3.19). The ob-
tained Bland–Altman %mean (+1.96 SD range) was −41 (−99.8 to
20.3). In the comparison between methods all results obtained from
the instruments were considered for regression parameters, also if the
aldosterone concentrations were below of the LoD values calculated in
the present study.
Table 3
Correlation matrix between consensus mean and plasma aldosterone values measured
with the immunoassay methods used by participant laboratories in the 12 control study
samples distributed in the EQA study.
CM SOR IMT LSN DRG DPC DSL IDSY
CM 1.000 0.994 0.966 0.964 0.759 0.958 0.977 0.990
SOR 0.994 1.000 0.937 0.981 0.710 0.976 0.988 0.989
IMT 0.966 0.937 1.000 0.875 0.845 0.896 0.899 0.947
LSN 0.964 0.981 0.875 1.000 0.626 0.965 0.994 0.972
DRG 0.759 0.710 0.845 0.626 1.000 0.645 0.652 0.738
DPC 0.958 0.976 0.896 0.965 0.645 1.000 0.966 0.958
DSL 0.977 0.988 0.899 0.994 0.652 0.966 1.000 0.974
IDSY 0.990 0.989 0.947 0.972 0.738 0.958 0.974 1.000
Abbreviations are identical to those of Table 2.
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In Table 2, the aldosterone valuesmeasuredwith the two automated
systems by the two reference laboratories in 12 control samples distrib-
uted in the annual 2013 cycle of the EQA Immunocheck study were re-
ported. For comparison, the aldosterone values measured in the same
control samples by the participant laboratories to the EQA study using
some RIA and EIA methods were also reported in Table 2. Furthermore,
the consensus means, which is the mean calculated considering all the
aldosterone concentrations measured by the participant laboratories
in the same sample after the exclusion of outlier values, were also re-
ported in Table 2. In Table 3, the correlationmatrix between the aldoste-
rone values measured with RIA and EIA methods by laboratories
participant to the EQA andwith the two automated platform by the ref-
erence laboratories were reported. All methods, with the exclusion of
the RIA method by DRG Instruments GMGH, were closely correlated
between themselves and with consensus mean values. In particular,
the results obtained with the two automated immunoassay methods
tested in the present study were highly correlated with consensus
mean values (for LIAISON method, R = 0.964, p b 0.001, and for iDYS
method, R = 0.990, p b 0.001). Moreover, the mean aldosterone values
measured with LIAISON method (367.2 ± 198.9 pmol/L) and iDYS
method (407.2 ± 287.2 pmol/L) were not signiﬁcantly different (p =
0.2163 by paired t test).
1.4. Clinical results
Aldosteronewasmeasuredwith the LIAISON platform in 168 plasma
samples of adult healthy subjects (65 men, age 48.0 ± 11.6 years; 103
women, age 48.0 ± 11.3 years). Considering the whole population,
the aldosterone concentrations corresponding to mean, median, inter-
quartile range, and 97.5th percentile values were 271.6 pmol/L,
234.9 pmol/L, 173.1–326.9 pmol/L, and 639.6 pmol/L, respectively.
Moreover, a signiﬁcant difference (p = 0.0144 by Mann–Whitney
U test) was found between the mean values of plasma aldosterone
found in women (290.6 ± 160.1 pmol/L, median 254.6 pmol/L) and
in men (241.3 ± 134.6 pmol/L, median 203.9 pmol/L), respectively.
Finally, a signiﬁcant negative correlation was found between age and
plasma aldosterone values (Rho = −0.238, p = 0.002 by Spearman
Rank Correlation test).
Blood samples were also drawn from 20 healthy subjects in a stand-
ing or supine position, aged 21–65 years. The standing samples were
drawn after the subjects had been walking for 2 h, and the supineTable 2
Aldosterone values measured by participant laboratories to EQA study in the 12 study
samples.
Study sample CM SOR IMT LSN DRG DPC DSL IDSY
Sample 01, pmol/L 107.5 181.9 48.6 171.1 90.8 86.9 93.1 157.2
Sample 02, pmol/L 119.4 186.7 71.9 149.2 109.7 81.1 141.1 123.6
Sample 03, pmol/L 200.3 256.7 176.1 189.4 114.4 121.1 189.7 123.1
Sample 04, pmol/L 211.1 269.4 – 210.3 118.9 126.4 217.2 166.9
Sample 05, pmol/L 238.3 371.4 156.9 300.6 180.6 245.8 319.2 230.8
Sample 06, pmol/L 262.5 374.4 163.6 292.5 323.6 245.6 273.6 259.2
Sample 07, pmol/L 330.8 454.4 331.7 296.1 199.7 305.3 298.9 335.0
Sample 08, pmol/L 340.8 454.7 372.2 309.7 236.4 415.8 325.0 372.8
Sample 09, pmol/L 630.8 844.7 541.4 660.3 243.3 634.4 725.0 722.5
Sample 10, pmol/L 662.8 861.1 566.7 704.2 265.3 607.8 764.2 828.1
Sample 11, pmol/L 674.2 857.2 657.2 563.1 420.3 549.4 645.6 780.6
Sample 12, pmol/L 690.6 807.5 832.8 559.2 680.0 516.4 637.5 795.0
Number of results 701 180 169 80 62 52 51 36
CM: consensusmean; SOR: ALDOCTK-2 RIA (DiaSorin, Saluggia, Italy); IMT: Immunotech/
Beckman Coulter RIA (distributed in Italy by Pantec Srl, Torino); LSN: LIAISON automated
platform (DiaSorin, Saluggia, Italy); DRG: Aldosterone ELISA (DRG Instruments GMGH,
Marburg, Germany, distributed in Italy by Pantec Srl, Torino); DPC: Coat-A-Count Aldoste-
rone RIA (DPC Biermann GmbH, Bad Nauheim, Germany, distributed by Siemens Health
Care Diagnostics, Germany); DSL: Aldosterone RIA (Diagnostic System Laboratories, Inc.;
Webster, USA, distribute in Italy by Pantec Srl, Torino); IDSY: iSYS automated platform
(IDS Ltd., Boldon, UK).samples were drawn after the subjects had been lying supine for
at least 1 h. The key parameters describing the distributions of results
obtained with iSYS and LIAISON methods are reported in Fig. 3 and
Table 4. Interestingly, there was a signiﬁcant difference between the
aldosterone values obtained in supine position with the two methods
(p b 0.0001 by paired t test), while the aldosterone values observed in
standing position were not signiﬁcantly different (p = 0.327) .
1.5. Discussion
RIA methods, commonly used for the measurement of aldosterone
in blood or urine samples, actually show some critical analytical issues,
such as long incubation times (up to 18 h), the need to assay several
samples together in the same run in order to minimize the cost, the rel-
ative short expiration date of radiolabeled reagents (usually less than
60 days), and the drawbacks related to the use of radioactive materials.
Our data demonstrate that the new competitive immunoassays for
aldosterone using LIAISON and iSYS platforms actually show better
analytical characteristics compared to RIA methods. In particular,
these fully automated methods can assay few samples in less than an
hour (TAT about 40 min), and the expiration date for reagents and
materials is usually more than 9 months for both methods. Further-
more, the results reported in Tables 2 and 3 demonstrated that the
immunoassays using LIAISON and iSYS platforms showed aldosterone
values highly correlated with the most popular RIA and EIA methods
used in the EQA study, as well as the consensus mean values obtained
in this multicenter study.
Moreover, the results of the present study indicate that the
new competitive immunoassays for aldosterone using LIAISON
and iSYS platforms showed similar analytical characteristics, such as
analytical sensitivity parameters (Table 1) and imprecision proﬁles
(Fig. 1). Moreover, the aldosterone values measured in 12 control
samples with these two methods were closely correlated with a mean
difference of 10.3% (mean difference, 40.0 pmol/L/mean concentration,
387.2 pmol/L, ×100), whichwas not signiﬁcantly different. On the other
hand, a signiﬁcant bias, which proportionally increases with the aldo-
sterone concentration, was found between these two methods, when
the aldosterone concentrations were measured in 290 plasma samples
of 91 healthy subjects and 199 patients with cardiovascular diseases
(Fig. 2B). The discrepancy between the results obtained with control
EQA samples and plasma samples of healthy subjects and patients,
may be due to different matrix effects (lyophilized materials vs plasma
samples). However, the larger number of plasma samples assayed by re-
ferral laboratories (i.e., 290), compared to lower number of control sam-
ples measured by participant laboratories to EQA scheme (only 12),
should take into account to explain these apparently conﬂicting results.
Indeed, although we found a proportional bias between the two auto-
matedmethods, whichwas statistically signiﬁcant (p= 0.0146), on av-
erage the percent difference between methods was relatively low
(15.0 ± 71.8%), and the linear correlation between the percent differ-
ence and the mean aldosterone concentration values, measured with
the two methods, was also relatively poor (R = 0.143) (Fig. 2B). These
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Fig. 3. Box plot and key parameters representing the comparison of aldosterone concentrations obtained with LIAISON and iSYS methods.
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due to the large number of plasma samples tested rather than the
matrix effects.
A relative limitation of this study is that different experiments were
performed (i.e., different replicates and number of samples) in the two
different referral laboratories, in particularwhen assessing performance
parameters, such as LoD, LoQ, and imprecision. On the other hand, the
strength of this study is the large number of experimental plasma sam-
ples tested (up to 290 in some evaluations) (Fig. 2) and the use of EQA
scheme results, including some hundreds of aldosterone determina-
tions performed by about 100 clinical laboratories using the most pop-
ular commercial aldosterone immunoassays in Europe (Tables 2 and 3).
This huge lot of data actually guaranteed robust statistical evaluations.
At present time, the measurement of aldosterone in plasma or urine
samples is recommended by international guidelines only for screening
of primary aldosteronism in patients at high risk for this clinical condi-
tion [3,4]. However, excessive tissue production of aldosterone occurs
in cardiovascular diseases, including myocardial infarction and heart
failure, resulting in a multitude of adverse effects in the cardiovascular
system necessitating pharmacologic blockade of this steroid hormone
[19]. Both human and animal studies have consistently proven the ben-
eﬁcial effects of aldosterone antagonist treatment on: 1) endothelial
function, 2) modulation of inﬂammatory mechanisms between blood
and the vascularwall and 3) reduction of tissue proliferation and cardio-
vascular remodeling leading to different severities of cardiovascular
damage [19]. According to these basic mechanisms of anti-aldosterone
therapy, some clinical trials reported some beneﬁcial effects of aldoste-
rone blockers in cardiovascular diseases, in particular in heart failure
patients, as recently reviewed [19–21]. More recently, several studies
evaluated the usefulness of this type of intervention in preventingTable 4
Distribution of supine and standing EDTA plasma aldosterone concentrations (pmol/L) in
20 healthy volunteers.
Method Position N Mean 95%CI Median Minimum Maximum
LiaisonXL Supine 20 175.8 154.7–196.7 180.6 111.1 244.4
Upright 20 333.6 276.9–390.3 306.9 183.3 583.3
iSYS Supine 20 87.5 59.4–115.6 72.2 25.0 183.3
Upright 20 315.83 231.1–400.3 291.7 105.6 797.2vascular and cardiac ﬁbrosis, myocardial hypertrophy and remodeling
in refractory hypertensive syndromes [22–24]. In these studies
[22–24] aldosterone levels were not usually measured, probably be-
cause RIAmethods are considered to be poorly suitable for large clinical
trials. However, it is conceivable thatmonitoring of aldosterone concen-
trations may be useful in patients with heart failure. Indeed, it is well
known that cornerstone drugs for management of heart failure, such
as ACE-inhibitors or angiotensin receptor blockers, may affect aldoste-
rone production or, as the case of aldosterone receptor blockers, antag-
onize its biological effects. In particular, after an initial decline, a stable
increase in aldosterone plasma levels has been reported to occur in up
to 40% of symptomatic heart failure patients on ACE-inhibitors or angio-
tensin receptor blockers [25]. This phenomenon was formerly termed
‘aldosterone escape’ by Pitt in 1995 [26], and recently renamed as ‘aldo-
sterone breakthrough’, to avoid the confusion with the “escape” from
the sodium-retaining effects of excess mineralocorticoids or aldoste-
rone in primary hyperaldosteronism. Aldosterone breakthrough is
clinically relevant, given aldosterone promotion of oxidative stress, en-
dothelial dysfunction, inﬂammation and ﬁbrosis, leading to cardiovas-
cular and renal injury. Indeed, a reliable measure of the aldosterone
could hold clinical relevance also in the heart failure setting.1.6. Conclusions
In conclusion, our data indicate that the two new automated
methods, evaluated in the present study, may be more suitable for
monitoring aldosterone levels in patients with cardiovascular diseases
than RIA methods, due to their better analytical performance in terms
of reproducibility and a shorter TAT. However, in our study signiﬁcant
bias was observed in result comparison, this means that translating
aldosterone concentration in clinical information an appropriate deﬁni-
tion of reference ranges for each method is mandatory.Authorship
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